-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVI-VZV-001 in Herpes Zoster (Shingles)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVI-VZV-001 in Herpes Zoster (Shingles) Drug Details: CVIVZV-001 is under investigation for the prevention of herpes...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Thematic Analysis
Consumer Goods M&A Deals Q3 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Consumer Goods Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amesanar in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amesanar in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Amesanar in Epidermolysis Bullosa Drug Details:Amesanar (Allogeneic ABCB5-positive mesenchymal stem cells) is acting...
-
Company Profile
NewWindtree Therapeutics Inc – Company Profile
Windtree Therapeutics Inc (Windtree Therapeutics) is a clinical-stage biopharmaceutical company that focuses on developing its drug product candidates for the treatment of pulmonary and cardiovascular diseases. The company’s lead development programs are istaroxime, for treating acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and lyophilized KL4 surfactant intratracheal suspension, both for treating respiratory distress syndrome (RDS) in premature infants; KL4 surfactant for the treatment of lung injury effected by sever Covid-19 infection; oral SERCA2a activators...
Add to Basket -
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. The NAFLD drugs in development market research report provides comprehensive information on the therapeutics under development for the NAFLD, complete...